The Bio Usawa Biotechnology (BUI) delegation, led by Dr. Menghis Bairu, CEO, had the honor of meeting with Botswana’s Vice President and Minister of Finance, Mr. Ndaba Gaolathe, MBA. The delegation presented its bold vision: establishing Sub-Saharan Africa’s first end-to-end platform for monoclonal antibody (mAb) biotherapies — ensuring that high-quality biosimilars for chronic and acute diseases become accessible and affordable. 

Vice President Gaolathe reaffirmed Botswana’s strong commitment to advancing biotechnology infrastructure and human resource capacity, creating opportunities to expand access to life-saving and life-altering medicines. He expressed his full support for Bio Usawa’s mission.

Redefining healthcare isn’t a dream — it’s happening. Made in Africa, for Africa.